INDP
Indaptus Therapeutics, Inc.
Price Chart
Latest Quote
$3.30
-0.25 (-7.04%)
Current Price
| Previous Close | $3.55 |
| Open | $3.58 |
| Day High | $3.65 |
| Day Low | $3.28 |
| Volume | 57,027 |
Stock Information
| Shares Outstanding | 113.24M |
| Cash Equivalents | $1.50M |
| Net Income | $-18.86M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $373.70M |
| EPS (TTM) | $-12.70 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $400.51M |
| Income | $-18.86M |
| Book/sh | $0.01 |
| Cash/sh | $0.01 |
| Employees | 5 |
Financial Ratios
| Quick Ratio | 1.60 |
| Current Ratio | 2.34 |
Returns & Margins
| ROA | -286.81% |
| ROE | -931.79% |
Ownership
| Insider Ownership | 96.93% |
| Institutional Ownership | 0.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.37 |
| P/B | 300.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $3.09 |
| SMA50 | $2.60 |
| SMA200 | $2.52 |
| RSI | 38.67 |
| ATR | 0.8989 |
| Shares Float | 3.24M |
| Short Float | 0.02% |
| Short Ratio | 0.19 |
| Volatility | 1.27 |
| Rel Volume | 0.02 |
Performance History
| Week | -26.67% |
| Month | +197.30% |
| Quarter | +87.50% |
| 6 Months | +62.56% |
| YTD | +20.44% |
| Year | -73.81% |
| 3 Years | -93.73% |
| 5 Years | -99.35% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $3.30 | 57,027 |
| 2026-06-24 | $3.55 | 124,000 |
| 2026-06-23 | $3.71 | 181,300 |
| 2026-06-22 | $3.78 | 162,600 |
| 2026-06-18 | $3.90 | 300,800 |
| 2026-06-17 | $4.50 | 749,100 |
| 2026-06-16 | $3.72 | 256,800 |
| 2026-06-15 | $3.69 | 377,200 |
| 2026-06-12 | $3.58 | 587,100 |
| 2026-06-11 | $3.57 | 4,238,800 |
| 2026-06-10 | $2.45 | 1,507,100 |
| 2026-06-09 | $2.03 | 1,585,600 |
| 2026-06-08 | $2.10 | 1,422,900 |
| 2026-06-05 | $3.66 | 2,792,000 |
| 2026-06-04 | $4.75 | 44,275,500 |
| 2026-06-03 | $2.21 | 97,900 |
| 2026-06-02 | $2.15 | 109,700 |
| 2026-06-01 | $1.92 | 140,600 |
| 2026-05-29 | $1.76 | 102,500 |
| 2026-05-28 | $1.44 | 55,900 |
| 2026-05-27 | $1.27 | 22,600 |
| 2026-05-26 | $1.11 | 64,900 |
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $19,833,513 | $15,365,751 | $16,378,474 | $14,910,906 |
| Other Income Expense | $-1,015,403 | $343,724 | $955,003 | $588,108 |
| Other Non Operating Income Expenses | $-1,015,403 | $343,724 | $955,003 | $588,108 |
| Operating Expense | $19,833,513 | $15,365,751 | $16,378,474 | $14,910,906 |
| General And Administrative Expense | $10,492,554 | $8,114,654 | $8,756,767 | $8,586,249 |
| Net Non Operating Interest Income Expense | - | - | - | $588,108 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Normalized Income | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Net Income From Continuing And Discontinued Operation | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Total Operating Income As Reported | $-19,833,513 | $-15,365,751 | $-16,378,474 | $-14,910,906 |
| Net Income Common Stockholders | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Net Income | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Net Income Including Noncontrolling Interests | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Net Income Continuous Operations | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Pretax Income | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Operating Income | $-19,833,513 | $-15,365,751 | $-16,378,474 | $-14,910,906 |
| Net Interest Income | - | - | - | $588,108 |
| Interest Income | - | - | - | $588,108 |
| Interest Income Non Operating | - | - | - | $588,108 |
| Per Share | ||||
| Diluted EPS | $-21.58 | $-45.08 | $-51.24 | $-48.44 |
| Basic EPS | $-21.58 | $-45.08 | $-51.24 | $-48.44 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-19,833,513 | $-15,365,016 | $-16,377,190 | $-14,909,125 |
| Reconciled Depreciation | $0 | $735 | $1,284 | $1,781 |
| EBITDA (Bullshit earnings) | $-19,833,513 | $-15,365,016 | $-16,377,190 | $-14,909,125 |
| EBIT | $-19,833,513 | $-15,365,751 | $-16,378,474 | $-14,910,906 |
| Diluted Average Shares | $966,124 | $334,132 | $300,037 | $295,075 |
| Basic Average Shares | $966,124 | $334,132 | $300,037 | $295,075 |
| Diluted NI Availto Com Stockholders | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Research And Development | $9,340,959 | $7,251,097 | $7,621,707 | $6,324,657 |
| Selling General And Administration | $10,492,554 | $8,114,654 | $8,756,767 | $8,586,249 |
| Other Gand A | $10,492,554 | $8,114,654 | $8,756,767 | $8,586,249 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,151,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Total Assets | $9,310,168 | $7,338,756 | $14,923,878 | $28,063,806 |
| Total Non Current Assets | $0 | $720,426 | $928,669 | $819,564 |
| Non Current Prepaid Assets | $0 | $638,251 | $754,728 | - |
| Current Assets | $9,310,168 | $6,618,330 | $13,995,209 | $27,244,242 |
| Prepaid Assets | $802,540 | $831,577 | $633,156 | $811,433 |
| Cash Cash Equivalents And Short Term Investments | $8,507,628 | $5,786,753 | $13,362,053 | $26,432,809 |
| Cash And Cash Equivalents | $8,507,628 | $5,786,753 | $13,362,053 | $9,626,800 |
| Other Non Current Assets | - | - | $754,728 | $738,251 |
| Assets Held For Sale Current | - | - | - | $0 |
| Receivables | - | - | - | $0 |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $0 | $84,164 | $175,053 | $80,494 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $73,348 | $0 |
| Current Debt And Capital Lease Obligation | - | $84,164 | $101,705 | $80,494 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,158,575 | $3,393,881 | $2,847,380 | $3,433,341 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $73,348 | $0 |
| Current Liabilities | $6,158,575 | $3,393,881 | $2,774,032 | $3,433,341 |
| Payables And Accrued Expenses | $2,133,234 | $1,938,219 | $1,459,273 | $2,136,605 |
| Payables | $628,157 | $870,229 | $846,004 | $1,507,245 |
| Total Tax Payable | $84,100 | $0 | $40,000 | $128,929 |
| Accounts Payable | $544,057 | $870,229 | $806,004 | $1,378,316 |
| Equity | ||||
| Common Stock Equity | $3,141,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Preferred Stock Equity | $10,000 | - | - | - |
| Total Equity Gross Minority Interest | $3,151,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Stockholders Equity | $3,151,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Retained Earnings | $-81,288,099 | $-60,439,183 | $-45,417,156 | $-29,993,685 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $96,434 |
| Other Equity Adjustments | - | - | - | $96,434 |
| Other | ||||
| Ordinary Shares Number | $2,167,324 | $429,067 | $300,037 | $300,037 |
| Share Issued | $2,167,324 | $429,067 | $300,037 | $300,037 |
| Tangible Book Value | $3,141,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Invested Capital | $3,141,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Working Capital | $3,151,593 | $3,224,449 | $11,221,177 | $23,810,901 |
| Capital Lease Obligations | $0 | $84,164 | $175,053 | $80,494 |
| Total Capitalization | $3,151,593 | $3,944,875 | $12,076,498 | $24,630,465 |
| Additional Paid In Capital | $84,408,018 | $64,379,770 | $57,409,643 | $54,443,705 |
| Capital Stock | $31,674 | $4,288 | $84,011 | $84,011 |
| Common Stock | $21,674 | $4,288 | $84,011 | $84,011 |
| Preferred Stock | $10,000 | $0 | $0 | - |
| Current Capital Lease Obligation | $0 | $84,164 | $101,705 | $80,494 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,025,341 | $1,371,498 | $1,213,054 | $1,216,242 |
| Current Accrued Expenses | $1,505,077 | $1,067,990 | $613,269 | $629,360 |
| Net PPE | $0 | $82,175 | $173,941 | $81,313 |
| Gross PPE | $0 | $82,175 | $173,941 | $81,313 |
| Long Term Capital Lease Obligation | - | $0 | $73,348 | $0 |
| Other Properties | - | $82,175 | $173,941 | $81,313 |
| Treasury Shares Number | - | - | $0 | - |
| Buildings And Improvements | - | - | $173,206 | $79,294 |
| Properties | - | - | $0 | $0 |
| Other Short Term Investments | - | - | $0 | $16,806,009 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-14,823,256 | $-12,323,188 | $-13,405,315 | $-13,078,347 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,823,256 | $-12,323,188 | $-13,405,315 | $-13,078,347 |
| Cash Flow From Continuing Operating Activities | $-14,823,256 | $-12,323,188 | $-13,405,315 | $-13,078,347 |
| Operating Gains Losses | - | - | - | $-24,155 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $17,140,568 | $-16,427,018 |
| Cash Flow From Continuing Investing Activities | - | $0 | $17,140,568 | $-16,427,018 |
| Net Other Investing Changes | - | - | - | $172,555 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,396,888 | $5,510,591 | $0 | $0 |
| Financing Cash Flow | $17,544,131 | $4,747,888 | $0 | $0 |
| Cash Flow From Continuing Financing Activities | $17,544,131 | $4,747,888 | $0 | $0 |
| Net Other Financing Charges | $-569,465 | $-762,703 | - | - |
| Net Preferred Stock Issuance | $6,000,000 | $0 | - | - |
| Preferred Stock Issuance | $6,000,000 | $0 | - | - |
| Net Common Stock Issuance | $6,396,888 | $5,510,591 | $0 | $0 |
| Common Stock Issuance | $6,396,888 | $5,510,591 | $0 | $0 |
| Other | ||||
| Issuance Of Debt | $5,714,800 | $0 | - | - |
| End Cash Position | $8,507,628 | $5,786,753 | $13,362,053 | $9,626,800 |
| Beginning Cash Position | $5,786,753 | $13,362,053 | $9,626,800 | $39,132,165 |
| Changes In Cash | $2,720,875 | $-7,575,300 | $3,735,253 | $-29,505,365 |
| Proceeds From Stock Option Exercised | $1,908 | $0 | - | $0 |
| Net Issuance Payments Of Debt | $5,714,800 | $0 | - | - |
| Net Long Term Debt Issuance | $5,714,800 | $0 | - | - |
| Long Term Debt Issuance | $5,714,800 | $0 | - | - |
| Change In Working Capital | $3,514,157 | $392,255 | $-518,073 | $-1,580,422 |
| Change In Other Working Capital | $-1,989 | $142 | $647 | $961 |
| Change In Payables And Accrued Expense | $2,848,858 | $474,057 | $-680,520 | $-1,154,829 |
| Change In Payable | $2,848,858 | $474,057 | $-680,520 | $-1,154,829 |
| Change In Account Payable | $2,848,858 | $474,057 | $-680,520 | $-1,154,829 |
| Change In Prepaid Assets | $667,288 | $-81,944 | $161,800 | $295,220 |
| Stock Based Compensation | $1,358,082 | $2,305,849 | $2,965,938 | $2,957,249 |
| Unrealized Gain Loss On Investment Securities | $1,153,421 | $0 | - | - |
| Depreciation Amortization Depletion | $0 | $735 | $1,284 | $1,781 |
| Depreciation And Amortization | $0 | $735 | $1,284 | $1,781 |
| Depreciation | $0 | $735 | $1,284 | $1,781 |
| Net Income From Continuing Operations | $-20,848,916 | $-15,022,027 | $-15,423,471 | $-14,322,798 |
| Income Tax Paid Supplemental Data | - | $1,600 | $1,600 | $2,400 |
| Net Investment Purchase And Sale | - | $0 | $17,140,568 | $-16,599,573 |
| Sale Of Investment | - | $0 | $24,000,000 | $13,000,000 |
| Purchase Of Investment | - | $0 | $-6,859,432 | $-29,599,573 |
| Change In Other Current Assets | - | - | $0 | $-721,774 |
| Other Non Cash Items | - | - | $-430,993 | $-110,002 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $-110,002 |
| Interest Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-23